-- UPC numbers assigned by Wolters Kluwer Health, provider of trusted clinical technology -- -- PoNS system and mouthpiece will be included in pharmacy database utilized by 17 out 20 of the top-grossing pharmacy benefit managers (PBMs) –-- -- PoNS expected to be one of few products with both
Company’s First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy Month NEWTOWN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech
-- The study will evaluate the optimal time to use PoNS Therapy™ during a patient’s stroke recovery journey -- NEWTOWN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic
-- Presentation to educate on Portable Neuromodulation Stimulator (PoNS ® ) Therapy, highlighting the differentiation from other neuromodulation technologies, and the science behind its effectiveness, clinical data, safety profile -- -- Forum brings together world experts from the core disciplines
NEWTOWN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on August 31, 2023, Helius
NEWTOWN, Pa., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-50 reverse split of its Class A
-- Total Q2 revenue up 115% over prior year; 131% over Q1 2023 -- -- Company to host call at 4:30pm today -- NEWTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic
Sixth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS Therapy™ for gait improvement in Multiple Sclerosis NEWTOWN, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies,
NEWTOWN, Pa., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its
-- Number of subjects increased from 12 to 60 -- -- Portable Neuromodulation Stimulator (PoNS®) will be used to evaluate cranial-nerve non-invasive neuromodulation and dynamic gait/balance in stroke patients -- NEWTOWN, Pa., July 27, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc.